Our leadership

Søren Tulstrup has served as President and Chief Executive Officer since March 2018. He has extensive experience as a senior executive in the global biopharma industry. Prior to joining Hansa, Søren served as Chief Executive Officer of Vifor Pharma AG (SIX: VIFN), (now part of CSL Behring), and he has also served as President & Chief Executive Officer of Santaris Pharma A/S (now part of F. Hoffmann-La Roche AG (SIX: ROG)). Furthermore, Søren has served in several senior general management and commercial roles within Shire Pharmaceuticals (now The Takeda Pharmaceutical Company Limited (TSE: 4502)), Merck & Co., Inc. (NYSE: MRK) and Sandoz Pharma AG (now Novartis AG, or Novartis (NYSE: NVS)) in both Europe and the United States. He holds a Master of Science, Economics and Business Administration from Copenhagen Business School. He was born in 1965.

Donato Spota has served as Chief Financial Officer since May 2019. He has more than 25 years of pharmaceutical industry experience in international environments, including strategic finance, business development, investor relations and international capital markets transactions. Prior to joining Hansa, he served in various roles at Basilea Pharmaceutica AG (SIX: BSLN), including as Chief Financial Officer. Prior to that, he held different finance roles at F. Hoffmann-La Roche AG (SIX: ROG). He holds a B.A. in Information Technology from the Swiss BBT (Bundesamt für Berufsbildung und Technologie) and an M.B.A. from the Hochschule für Wirtschaft und Umwelt Nürtingen-Geislingen. He was born in 1971.

Anne Säfström Lanner has served as Chief Human Resources Officer since June 2020, and served as Vice President Global Human Resources from 2019 to June 2020. Prior to joining Hansa, she served in various senior roles at the European Spallation Source, a European multi-disciplinary research facility, including Head of Resourcing. Prior to that, Head of Human Resources at Cellavision AB (STO:CEVI). Anne has held positions as Head of HR, Head of Resourcing, HR Manager & Deputy Head of HR and has extensive experience from fast growing start-up international companies. Holds a Bachelor of Social Science in Human Resource Management, focusing on strategic organizational development & leadership, from Lund University. She was born in 1969.

Matthew Shaulis has served as Chief Commercial Officer and President of the U.S. affiliate, Hansa Biopharma Inc since March 2023. Prior to his role at Hansa Biopharma, Matthew gained over 20 years of US and international experience in the pharmaceutical industry in general management, global strategic and in-line marketing, sales management, business development, and product and indication launches. He held several senior executive roles at Pfizer Inc. (NYSE: PFE), including President of Inflammation & Immunology for International markets in Europe and Asia, President of Oncology for North America, and more recently as the Senior Vice President responsible for leading the company’s global commercial and medical go-to-market model transformation. Prior to that, Matthew served in various leadership roles at Teva Pharmaceutical Industries (NYSE: TEVA), Cephalon, Johnson & Johnson (LSE: JNJ), and Schering-Plough (now part of Merck & Co., Inc. (NYSE: MRK)). He holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from The Fuqua School of Business, Duke University, North Carolina. He was born in 1973.

Shareholding: –
Share rights: –
ESOs: –

Achim Kaufhold has served as Chief Medical Officer since June 2020. He is a highly experienced senior leader in immunology, infectious diseases and oncology. Achim has over 25 years of international experience within the biotechnology and pharmaceutical industry. Prior to joining Hansa, Achim served in various senior executive positions in general management, product and business development. Has served as Chief Executive Officer of Affitech AS and Pharmexa A/S (both companies merged), Chief Medical Officer of Basilea Pharmaceutica AG (SIX: BSLN), Pharmexa A/S, Chiron (acquired by Novartis (NYSE: NVS)) and Berna Biotech AG (now Johnson & Johnson (LSE: JNJ)). Prior to that, he headed the worldwide clinical development of the pediatric vaccine portfolio of GlaxoSmithKline plc (LSE: GSK). Currently also serves on the board of directors of Biosergen AB (STO: BIOSGN). Graduated as a Doctor of Medicine from the University of Cologne and holds a professorship in Medical Microbiology and Infectious Diseases at the University of Aachen, Germany. He was born in 1957.

Shareholding: -
Share rights: 81,000
ESOP's: 94,000

Peter Nicklin has more than 30 years of extensive experience and background in the pharmaceutical and healthcare sector in both developed, as well as emerging markets and significant experience in leading global teams. Chair of the Board at Tunstall Healthcare and Sciensus. Previously, CEO and member of the Board of Amann Girrbach AG, Corporate Vice President and EMEA President of Baxter International (NYSE: BAX), as well as senior executive roles at Bayer Healthcare (XETRA: BAYN), Novartis (SWX: NOVN) and Bristol-Myers Squibb (NYSE:BMY). Peter holds a Bachelor of Arts with Honours in Finance from Lancaster University. He is also a Chartered Accountant having qualified at PriceWaterhouseCoopers in London. He was born in 1963.

Member and chair of the Board since 2022, member of the Remuneration Committee, the Scientific Committee and the US Committee. Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.
Shareholding: 14,500

Eva Nilsagård is the founder and Chief Executive Officer of Nilsagård Consulting AB. Previous interim Chief Financial Officer of various companies, including OptiGroup AB, Plastal, and Vitrolife AB. She has also served in various senior positions at the Volvo Group, or Volvo, including Senior Vice President Strategy & Business Development. Earlier in her career, Eva also held senior positions in finance and business development at AstraZeneca plc and AB SKF. Board member and chair of the audit committee of SEK (Swedish Export Credit Company), AddLife, Bufab Group, Irras AB, Nimbus Group AB, Nanexa, Ernströmgruppen and Xbrane Biopharma, the chair of Spermosens AB and Diagonal Bio AB, and board member of eEducation Albert AB. Eva has more than ten years of
experience as a mentor for young female managers with high potential. She holds an Executive M.B.A. in Economics and a B.Sc. in accounting and finance from School of Business, Economics and Law in Gothenburg. She was born in 1964.

Member of the Board since 2019 and chair of the Audit Committee.
Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.

Shareholding: 3,000

Shareholding: 1,000

Hilary Malone has over 25 years of experience in global drug development, regulatory and government affairs, manufacturing and commercialization within the pharmaceutical industry. She has served as Chief Executive Officer of a private life sciences company in start-up phase since November 2021. She previously served as Chief Operating Officer and Executive Vice President at Valo Health Inc., and as the Chief Regulatory Officer and Senior Vice President & Head of Global Regulatory Affairs at Sanofi Inc. (subsidiary of Sanofi SA). Previous experience also includes senior regulatory and drug development roles at Reata Pharmaceuticals, Inc., Pfizer Inc., Wyeth, LLC (acquired by Pfizer Inc.), AstraZeneca plc and GlaxoSmithKline plc. Hilary has also served on the board of Inhibikase Therapeutics. She holds a Ph.D. in Molecular Neuropharmacology and a B.Sc. in Physiology from the University of Dundee, Scotland. She was born in 1965 and is a U.S., U.K., and Irish citizen.

Member of the Board since 2021, chair of the US Committee, and member of the
Scientific Committee.
Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.

Shareholding: -

Andreas Eggert has over 25 years of cross-functional leadership experience including commercial operations, launch and portfolio management, brand strategy, market access, and strategic consulting. Chief Operating Officer at X-Vax Technology Inc. in the U.S. Previously, served as Senior Group Vice President, Global Product Strategy & Portfolio Development, and member of the Corporate Management Committee at H. Lundbeck A/S in Denmark. Previously, also served in various senior commercial roles at Wyeth, LLC (acquired by Pfizer Inc.) in the U.S., Japan and in Germany, including as Vice President & Global Business Manager. Earlier in his career, Andreas also was a Management Consultant at A.T. Kearney. He holds an M.B.A. from Azusa Pacific University. He was born in 1967.

Member of the Board since 2018, chair of the Remuneration Committee, and member of the Audit Committee and the Scientific Committee.
Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.

Shareholding: 5,500

Anders Gersel Pedersen has over 33 years of experience in the international pharmaceutical industry. Served in various roles at H. Lundbeck A/S in Denmark (CSE: LUN), including most recently as Executive Vice President of Research & Development, as responsible for the discovery and development of the product pipeline from preclinical activities to post-launch marketing studies. Prior to that, served in various roles at Eli Lilly and Company, including most recently as a director overseeing worldwide clinical research in oncology. Member of the European Society of Medical Oncology, the International Association for the Study of Lung Cancer and the American Society of Clinical Oncology. Serves on the supervisory boards of Avillion LLP, Bavarian Nordic A/S, AELIS Farma SA, and Genmab A/S. He received his medical degree and a doctoral degree in neuro-oncology from the University of Copenhagen and a B.Sc. in Business Administration from Copenhagen Business School. He was born in 1951.

Member of the Board since 2018, chair of the Scientific Committee, and member of the Remuneration Committee.
Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa

Shareholding: 2,500